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The broad range of chemical and biological compliance standards has resulted in 
a complex, multifaceted regulatory environment for the development and distribution of 
biological products. Due to this complexity, company processes are challenged with the 
task of developing procedures to meet the technical regulatory requirements, but still 
allow personnel to consider cross-functional business applications. The conceptualization 
of this regulatory model can be increasingly difficult for new or less experienced 
personnel for the reason of a lacking foundation of fundamental regulatory elements. 
Thus, the purpose of this Capstone Project was to create a biological handbook that can 
be used as a reference guide for regulatory considerations of biological product. This 
handbook was designed to bridge the knowledge gap between developing procedures and 
providing appropriate resources and basic information for key personnel.  
 The development of this handbook required the compilation of current regulations 
and Company processes, to then delineate, to use as a reference tool specific to the Texas 
logistic center. Guidance documents published by regulatory agencies were reviewed and 
provided useful interpretations of otherwise dense regulations. A search for other broad 
reference documents related to biological substance organization was unsuccessful. Each 
chapter provides a different regulatory aspect of biological products, some of which 
would require trigger collaboration between business functions. The project resulted in 
the creation of handbook, intended to provide basic information that may apply to 
biological operations conducted at the current logistics center and internationally 
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Code of Federal Regulations: A collection of rules and regulations promulgated by 
Federal executive agencies. Published in the Federal Registrar, the CFR is divided into 50 
titles, each then subdivided by a broad range of subject matter. An editorial compilation 
of CFR material is available online as the Electronic Code of Federal Regulations (e-
CFR). 
For Research Use Only: A Research Use Only (RUO) label is designated for products 
that are intended only for research laboratory use. The FDA defines RUO products as “in 
the laboratory research phase of development and not represented as an effective in vitro 
diagnostic product.”1  
In Vitro Diagnostics: Any device, reagent, material or system that is designed for 
laboratory diagnostics. 2 
Recombinant DNA/RNA: Commonly referred to as rDNA or rRNA, refers to the 
process of which the biologic genome being artificially created. Molecules of DNA/ 
RNA are formed in laboratory and purposefully bring genetic material together, 





                                                          
1 Medical Devices, U.S. Code of Federal Regulations, 2019, Title 21, sec. 809.10.5 (i) 
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Chapter 1. Introduction 
1.1. Background  
Biotechnology is a synonymous term used to describe a vast array of scientific 
innovations developed around the use of cellular and biomolecular processes to improve 
the quality of life.3 As there becomes a broader range of applications and market demand 
biotechnology continues to offer promising advancements for the future; with the 
potential of improving medical, pharmaceutical, agriculture and environmental 
challenges. The use of biotechnology is not a new concept; it is safe to say we have far 
surpassed the basic concepts of fermentation and vaccinations that have evolved into our 
current modern biotechnology market. The production and quality process of biologic 
products focus on the nature of the product and its relevant discipline.4 
By statute, a biological product includes a virus, therapeutic serum, toxin, 
antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein 
(except any chemically synthesized polypeptide), or analogous product, or arsphenamine 
or derivative of arsphenamine (or any other trivalent organic arsenic compound), 
applicable to the prevention, treatment, or cure of a disease or condition of human 
beings.”5 By this definition, biological products differ from synthesized small molecular 
chemical drugs because chemicals are well-defined structures and thoroughly categorized 
using a Chemical Abstract Service (CAS) registry. Biological products are originated 
from natural living material such as human, animals, and microorganisms, making them 
                                                          
3 "What Is Biotechnology?,” Biotechnology Innovation Organization, Last modified 2019, 
https://www.bio.org/what-biotechnology.  
4 "Biological Safety,” National Institute of Health, Last modified 2019, 
https://www.ors.od.nih.gov/sr/dohs/safety/laboratory/BioSafety/Pages/bio_chem_safety.aspx.  




difficult to categorize and track in the same methods as chemicals. Implementation of 
quality systems such as good manufacturing practices (GMP) offers biological product 
quality and insurance to consumers of acceptable, well- recognize policies and 
procedures. 
Domestic oversight of biological products is provided by the Food and Drug 
Administration (FDA), organized by various centers and offices to focus on specific 
types of products and their marketed use.  Biologic and medical device regulations are 
statute to Part 21 of the Code of Federal Regulation (CFR). Generally, regulated 
biological products respectively fall into the jurisdiction of the following FDA centers: 
Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and 
Research (CDER), or Center for Devices and Radiological Health (CDRH).6 
International compliance authority and applicable regulations are dependent on the 
importing country and region. Each country with its own set of subject matter needed to 
successfully ship and import/export products without delay, product seizures, and 
potential for noncompliance citations, and subject to civil or criminal penalties.7  
There is a need for a cohesive relationship across scientific, regulatory, business 
and logistical operations to create successful global importing/exporting outcomes. 
Coordination of this level builds a complex matrix that can be overwhelming and difficult 
to navigate without a clear point of origin that is needed to relay information in an 
organized manner across business functions.  
                                                          
6 U.S. Food and Drug Administration, FDA Overview Organization Chart, image, 2019, 
https://www.fda.gov/about-fda/fda-organization-charts/fda-overview-organization-chart.  




1.2. Statement of the Problem 
There are a large variability and range of use for biologics; each has its own 
subplot of highly technical, regulated and complex operational activities.  This requires a 
collective diversity of skills and background from many people to meet the broad scope 
of needs for product development and planning throughout the product lifecycle. This 
means that while scientists and product developers may be an integral element of a 
successful biotech company, not all personnel share the same specific experience for all 
marketed types of biological product manufacturing needs. Without a thorough 
understanding of applicable regulatory requirements and regulations, a company or 
institution may be left at risk of product quality, noncompliance, shipment holds, and loss 
of revenue.  
In addition to the central personnel, there should be a resource of fundamental 
material of biological product requirements/elements when introducing new or less 
experienced employees the principle and practices related to the specific nature of a 
product. To the inexperienced, the macro-level of biotechnology can appear as a vast 
multi-dimensional environment, causing one to be left overwhelmed in the operations and 
lacking rationale. Thus, the author has designed a handbook for research administrators 
with the emphasis on easy access and readability. Access and readability are imperative 
to further understand the complex organizational structure and the methodology behind 
any company’s policies and procedures, focusing on the regulatory and project 
management considerations.  
Additionally, the author’s current company encompasses multiple regulatory 




manufacturing. Their business continues to expand by way of merger and acquisitions or 
through the development of products by their current research and development teams. In 
turn, the company growth results in operational changes that must be acknowledged for 
proper restructuring.  
1.3. Project Questions 
FDA provides oversight and regulations to a vast array of consumer products, 
many of which can be classified under biologic products. Regulatory authority is 
determined by its classification or type and its intended use. To create a handbook that 
includes an exhaustive review of regulatory content is not practical. Therefore, the 
primary project question for this Capstone Project was: 
What elements should be included in this handbook to provide an effective 
overview of biologic product resources and considerations?  
If the handbook is to provide information for key personnel as well with varying 
backgrounds: 
 What level of readability and complexity should the content be formatted?  
1.4. Project Objectives  
 The primary objective of this project is to generate a handbook for use by the author’s 
current place of employment as a centralized resource of essential biological information and 
considerations for researchers, regulatory administrators, or other applicable professionals. This 
handbook provides a centralized resource which is approached from a regulatory and 





 This project is significant to the author and research administrators because it 
documents and presents the challenges met over the past year during the author’s career 
transition into the biotechnology industry. Despite the wealth of knowledge spread across 
the Company, there is not a single fundamental guide in biological product considerations 
for the use of diagnostic and life science products which a research administrator can 
access. While for some, relying on technical process documents as the foundation of 
further organizational roadmaps is not productive. Thus, there was a need for a biological 
handbook.  
 This biological handbook was designed to fill the gap of meeting the need to 
integrate applicable biologic product regulations with other functional areas in order to 
effectively collaborate during the manufacturing and disbursement of RUO and IVD 
biological products. This handbook is designed to be utilized as an onboarding training 
tool, reference tool, and guide for research administrators working in biotechnology.  
1.6. Exclusions and Limitations.  
 The inherent complexity of biological products does not allow a handbook to 
include all biological regulatory references and operational considerations. Therefore, in 
an effort to build a handbook that can be used with the author's current Company needs 
biological product information will be limited to biologics labeled as:  
• Research for Use Only (RUO), Not to be Used in Diagnostics Testing 




Although products manufactured at the current location include a limited number of IVD, 
ASR and GPR products that contain biologic substances; each product type could 
respectively need its own handbook. To credit these product types general information 
regarding IVD, ASR and GPR products was included. 
• Vitro diagnostic (IVD) products (limited information) 
• Analyte Specific Reagents (ASR) 
• General Purpose Reagents (GPR) 
Limiting the biological product by type allowed the Handbook to provide examples of 
international shipping elements and other bodies of regulatory oversight. Accordingly, 
this handbook provides information for biological products while importing essentials 




Chapter 2. Literature Review 
 
2.1. Overview of literature review.  
A preliminary review of literature for this project focused on methods to 
understand fundamentals of biological products, bodies of regulatory oversight and 
management skills of bio-manufacturing in effort to provide information and best 
practices for specific biological products. FDA guidance documents regarding labeling 
applicable to Company products. These publications were reviewed against current 
Company process documents or standard operating procedures (SOPs) found to ensure 
relevance. The result of this review supplied a framework of basic information to be 
referenced or later built-upon as experience and knowledge develop.  
 An additional review was completed in effort to locate similar guidance material. 
This was completed to ensure inclusion of additional elements that may not have initially 
been identified or provide the author with a preconceived structure for relying the 
information in a clear and concise manner.  
2.2. Regulations that Apply to IVD-RUO Products 
 The FDA Guidance document Distribution of In Vitro Diagnostic Products 
Labeled for Research Use Only or Investigational Use Only outlines the statutes for IVD 
exemptions for RUO labeling. Generally, IVDs are subject to medical devices federal 
regulations 21 CFR 862, 21 CFR 864 and 21 CFR 866. Each IVD categorized as a Class 
I, II or III according to the level of control necessary to ensure safety and the efficacy of 
the product. Each classification determines the appropriate premarket approval process.8,9 
                                                          
8 “Overview of IVD Regulations,” U.S. Food and Drug Administration, last modified September 16, 2019, 
https://www.fda.gov/medical-devices/ivd-regulatory-assistance/overview-ivd-regulation#2  




In vitro diagnostics can be reagents, instruments, or systems intended for the use in 
diagnosis of diseases by collection, preparation, and examination of specimens taken 
from patients in the human body.10 
The exemption requirements for an RUO IVD are much more extensive than the 
intended use labeling, 21 USC 360j(g) and section 520(g) of the FD&C Act provide the 
necessary requirements for a device exemption. Not all devices are eligible for 
exemption, device exemption applications must be submitted and granted by the Health 
and Human Services (HHS).  
 By classifying a product as RUO, it implies the product and its application is only 
intended in the use in discovering or developing knowledge related to diseases or other 
human conditions as long as the product and its use support the research instead of 
produce results for clinical or diagnostic use. There are various types of products that 
may be labeled as RUO, such as: reagents, instruments, and systems.11   If in accordance 
with 21 CFR § 809.10(c)(2)(i) an IVD may be labeled as RUO if “a product in the 
laboratory phase of development, and not represented as an effective in vitro diagnostic 
product.”  
 What is important to note about RUO products is that they are exempt from most 
regulatory controls and do not related to any mandatory standards for product quality and 
validation or good manufacturing practices. Even so, the lack of FDA jurisdiction does 
not exempt RUO products from abiding by chemical and biological transport regulations, 
global trade classification or possible foreign country restrictions (e.g. EU Directives).  
                                                          
10 21 CFR § 809.3 
11 U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Distribution of In 
Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Guidance for 




2.3. Review of Similar Documents and Details 
The author was unsuccessful in locating guidance documents with a similar 
objective of the project handbook. However, academic institutional manuals regarding 
biological shipping processes were discovered and used in the development of biological 
consideration because similar standards apply.  
Biological Shipping Manuals: 
• Desert Research Institute (DRI): Guideline on Classification of Biological 
Materials for Shipment 
• Dartmouth: Guide to Shipping Biological Materials 
• University of Pennsylvania: Shipping Manual for Infectious Substances, 
Biological Materials 
• Augusta University: Guide to Shipping Biological Substances and Materials 
2.3.1. Guidelines on Classification of Biological Materials12 
Biological guidelines provided by DRI highlights the general overview of 
biological material categorization as it relates to domestic transportation regulations. The 
scope of information was limited to information, no instructions were included. The 
simplicity of the guidance document allowed for a clear review of shipping categorization 
for domestic needs. Documentation was published in 2015, with no reference citing for 
biological shipping classifications steps. Additionally, review of manual verse current 
regulations was conducted to ensure it is it still current with federal regulations.  
                                                          





2.3.2. Guide to Shipping Biological Materials13 
Guidance document provided by Dartmouth included a thorough review of 
information related to labeling and packaging details. The documentation provided visual 
aids for proper packing needs for each type of biological material to emphasis the impact 
on the safety of the human, animals, and environment for any regulated substances.  
2.3.3. Shipping Manual for Infectious Substances, Biological Materials14 
Building upon Dartmouth’s Guide to Shipping Biological Materials, the shipping 
manual provided by the University of Pennsylvania concentrates information around the 
relationship of infectious substances and dangerous goods. In addition, it considers the 
best practices for shipping restrictions and emergency response steps for improper 
packing.  
2.3.4. Guide to Shipping Biological Substances and Materials15 
The largest of the reviewed guidance documents, the Augusta University manual 
is a process manual that may be used for extramural shipping needs. The guidance 
expands on environment and health safety considerations and penalties of 
noncompliance. 
                                                          
13 "Guide to Shipping Biological Materials,” Dartmouth.Edu, accessed November 1, 2019, 
https://www.dartmouth.edu/~ehs/biological/biosafety_docs/shipping_guide.pdf.  
14 "University Of Pennsylvania Shipping Manual For Infectious Substances, Biological Materials,” 
Ehrs.Upenn.Edu, Last modified 2017, https://ehrs.upenn.edu/sites/default/files/2018-
02/Shipping%20October%202017r_0.pdf.  
15 "Guide To Shipping Biological Material Substances And Support Materials (Section 10-AU Biosafety 






2.4. Applicability of Literature Review.  
All documents supplied the basis of product stewardship and presented a similar 
outline of information. However, each guidance document review builds upon the last, 
allowing a steady flow of learning when developing a method to organize these 
processes. It should be noted, the perspective of all documentation is provided from an 
academic institution. As an industry company that manufactures biologics products for 
marketability the need to continuously define the regulations would provide a more 
beneficial impact.  
 Given the amount of regulatory content applicable to RUO and IVD biological 
products, not including international regulations, it is clear that a handbook would benefit 
the Company by reducing time spent on searching through various governing websites 





Chapter 3. Need(s) Assessment 
 
3.1. Establishing the Need  
 The Company offers biological process documents, many of which stay in draft 
mode due to the ever-changing regulatory environment. Because of this, new projects are 
frequently started to restructure product import and exporting needs in an effort to find 
more efficient methods of bringing products to market. The Company’s regulatory 
department(s) are compartmentalized across location and product application barriers. In 
turn, this results in a lack of standardization in procedures and training tools and has 
shown significant overlap in efforts across the organization. It is the author’s hope that 
the need for this handbook with centralized information may create the basis of 
standardization because it only contains the framework of operational requirements. 
3.2. Metrics. 
 Specific metrics were not used to determine the need for a handbook. Instead, this 
project is meant to serve as a reference of information applicable to RUO and IVD-RUO 
biological product regulatory and operational considerations during the planning 
throughout the product lifecycle. After continued use, metrics can be established to 
determine the impact of the handbook by providing data relating to the frequency of use, 
ease of access, and readability by use of end-user satisfaction surveys.  
3.3. Sources Consulted.  
The handbook is formatted to provide information to both experienced and new 
personnel. It is designed to provide specialized information to fill in any gaps in 
knowledge that a research administrator may have regarding fundamental biologic 




as the Product Regulatory Affairs Manager of Genomics Solutions Biomolecular 
Analysis Divisions (BAD) were consulted during the conception of this project. Both 
individuals have extensive experience in the area of regulatory affairs and quality 
assurance of medical devices.  
3.4. Committees.  





Chapter 4. Project Description  
4.1. Discussion of Project Elements  
The elements of this project included the creation of a Handbook made up of a 
compilation of definitions and regulatory resources that apply specifically to RUO and 
IVD-RUO biological products. The Handbook organizes the information from applicable 
basic definitions to regulatory considerations that may impact product shipments. 
Because of the vast array of biological products, intended use, export/import regulations, 
the Handbook will only account for the European Union/Germany and South Korea’s 
international regulations. The Handbook focuses on sources and material that the author 
has found beneficial in developing an understanding of biological product concepts. The 
objective of this project is to develop a Handbook that could serve as a valuable reference 
guide for others.  
A secondary element of this project was to provide the content in a clear, concise 
and easily readable format. The information was presented with flow-charts and 
examples when applicable in hope of by offering the information in a different form may 





Chapter 5. Methodology 
5.1. Methodology Overview  
The development of this Handbook required a thorough review of company 
policies and procedures, both federal and international regulations and other previously 
published biological guidance documents and manuals. Upon completion of review, it 
was determined that even by narrowing the scope by a product's intended use, there were 
still far too many elements for the Handbook to be considered an exhaustive compilation 
of regulatory needs. This is because operational, regulatory affairs activities touch every 
aspect of the product lifecycle. It was determined that the Handbook was to be developed 
with consideration of specific workplace applications that would benefit from such a 
guide, as such the handbook should not be considered exhaustive to all biological 
regulatory functions. Upon completion of the first draft, the previously listed consulting 
sources reviewed and provided feedback to ensure the appropriate coverage of relevant 
elements. The final draft version of the Handbook was disbursed to author’s colleges for 
additional review and to determine the functional use for end-users. 
5.2. Discussion of Handbook  
The Handbook includes a total of nine chapters that are intended to provide 
definitions, references, and operational considerations when shipping RUO and IVD 
biological products; emphasis on South Korea and the EU (specifically Germany) import 
examples. The introduction to the Handbook is meant to express the intent of the 
assimilated material and provide the topics available for reference. Because the material 
differs from a manual or process document it does not require to be read in succession 




users to access topics of interest easily for general guidance. Even so, the layout of the 
chapters is provided with fundamental information in the beginning that is built-upon to 
interpret the information in later chapters. 
  Chapter 1 supplies basic and broad definitions that may be useful for new or less 
experienced employees. The terms are focused around common chemical, biological, and 
manufacturing terms that the author has compiled throughout their own continuous 
training within the Company. For example, asking “what is a biologic” can be provided 
with a direct response that the Company has defined as well as reference that to help 
understand the product type descriptions provided in Chapter 2.  
Chapter 3 supplies information and references on the identification of biologics 
and organized into their respective classifications for regulatory oversight. Classifications 
may differ from the US, EU, and South Korea, resulting in different documentation 
required to stay compliant with both domestic and international requirements. For 
example, biologics are derived from microorganisms, plants, or animals, many of which 
are produced using recombinant DNA/RNA. The variation between the biological origin 
and if its synthetic may dictate a classification. 
The FDA functions as a basis for established US regulations of many products, 
but product compliance may also need to consider non-FDA issues that can impact 
operations. Chapter 4 brings awareness to domestic agency oversight by identifying both 
FDA regulations by its respective centers in addition to national transportation 
compliance aspects. It should be noted that state-level regulations are not included in the 




The company supports 32 countries, of which only two are acknowledged and 
given a high-level overview. The capabilities to effectively evaluate the risk for new 
biological and chemical products requires a specific scope of capabilities and workforce 
that the company chooses to outsource to third-parties. Chapter 5 identifies consulting 
companies the Company contracts to support chemical and biological product needs. 
Shipping products internationally requires its own set of regulatory compliance 
hurdles. Chapter 6 identifies the international and foreign regulatory authorities in the EU 
and South Korea with their appropriate customs, regulations, and standards needed to 
import from the US. This is not easily determined though some countries attempt to 
harmonize their regulatory processes in hopes that by standardization, there leaves less 
room for varied interpretations and noncompliance. The severity of noncompliance 
differs for various countries; Chapter 7 outlines the legal considerations of importing 
products with noncompliance. 
Some biological products require licensing or specific permits because of their 
intended use or content. This is to ensure the safety and quality of products during their 
shipment and end-use process. Chapter 8&9 provides manufacturing and product 
information and resources on quality controls and risks that must be considered during 
their production and before shipping with biological content regardless of a domestic or 
international destination. 
As previously stated, due to the nature of biologics, they are not as easily 
categorized as a chemical for regulatory purposes. Chapter 9 discusses some of these 





Chapter 6. Project Results and Discussion 
This project resulted in the creation of a handbook to help new or less experienced 
research administrators in navigating biological products regulatory elements. The 
handbook is a compilation of statutory references and guidelines that are meant to be 
quickly utilized for biochemical product areas within a question. Throughout the authors 
career transition into the biotechnology industry from clinical research provided many 
challenges in navigating appropriate resources when assimilating to the new regulatory 
environment. All the literature and information reviewed during the development of this 
project only further acknowledged the complexity of the biological product lifecycle. It 
was identified early on in the project that the handbook could not include information for 
all types of biologics or even all stages of the biological lifecycle, instead it is focused 
from the perspective of the author and fellow coworkers to utilize for general resources. 
  Through discussions and feedback provided by the consulting sources, it was also 
acknowledged that the intellectual property of the Company’s compliance processes 
being publicly available is not within the best interest because of a competitive 
marketplace. This concern resulted in a need to keep the Company unidentified and 
attempt to generalize business strategies or management concepts that would otherwise 





Chapter 7. Recommendations  
All recommendation is based on the research, personal challenges, and source 
feedback that the handbook presented itself with during development.  The 
recommendations are largely based around the need to define and establish processes 
surrounding the health of this documentation and methods of ensuring its usefulness for 
the future. The desire of a handbook to be utilized as a central means of information 
began with the Company’s current challenge of keeping relevant information available 
and accessible to everyone.  
7.1. Recommendation 1: Establish Ownership of Handbook and Assign Updating of 
Handbook to a Single Entity 
The regulatory landscape is continuously changing; the challenge to stay 
compliant is at constant risk. Although the Company chooses to use third-party providers 
in tracking and navigating global regulations, internal controls must be reviewed to 
ensure they are covered. For the Handbook to be a useful resource, it must be mapped 
into the internal review process during applicable regulatory updates. There is not a 
document management platform at this current company, all processes are updated 
manually. By establishing genomics regulatory team ownership, given in 
recommendation one, the team governs the process performance of the handbook and 
will be reviewed on a bi-annual basis. 
It would not be ideal to include this documentation with formal change controls 
since that would allow it be part of the auditing system. Instead this document should 





There are various regulatory departments within the Company, each with its own 
processes. By producing a reference tool that sources key contact information for other 
departments, it must be agreed upon they each take responsibility of actionable items that 
may result from referencing this handbook. However, the accuracy and updating of this 
handbook must be assigned to a single entity. Assigning responsibility allows for 
changes, updates or questions to be addressed in an organized manner. The 
recommendation to establish departmental ownership allows them process governance 
for the relevancy of the handbook.  
If the Company decides to break their current, siloed approach to product 
development the Handbook may then be valued as a central resource of information in 
order to integrate other department process or considerations.  
7.2. Recommendation 2: Future Development of the Handbook 
As a means to be a valuable resource for varying levels of experienced staff, there 
was a strong emphasis on providing the information in a manner that allowed for quick 
access to crucial elements and ease of readability. The handbook needs to be kept up to 
date. The Company must enable the handbook to grow within other applicable areas of 
regulatory concerns, for example, supporting new countries with entirely new regulations 
that can be added into the current handbook with ease because the information does not 
directly relate to specific process. The handbook outlines information in a meta-data form 
that will allow for straightforward navigation, even if more information is added or 
changed.  
This recommendation is a real scenario that the Company faces regularly. As 




include new variables. Adding one new element may require a complete restructuring 
because of its downstream impact but this requires the rework of multiple documents 
across multiple platforms. 
7.3. Recommendation 3: Company Needs to Develop a Process for End-User 
Feedback into the Content of the Handbook  
Once available as a finalized document, a larger pool of end-user feedback is 
possible and should be encouraged. This element was important to the author because the 
opportunity to allow feedback invites collaboration with more experienced counterparts. 
As the author noted, this project resulted in identifying gaps and challenges the author's 
current knowledge of biological product concepts. Providing a culture of continuous 





Chapter 8. Conclusion 
 The development of biological products requires a multifaceted approach to stay 
in compliance with the many regulatory aspects. As one of many biotechnology 
companies that develop and distribute some variation of products that contain biologic, it 
is critical to understand applicable regulations that lead to its specific operational 
activities. Given the complexity and variability, it may be difficult to distinguish a 
starting point and only then navigate to applicable regulatory requirements. While biotech 
companies generally contain professionals with a scientific background, the degree of 
knowledge and understanding can be diverse. Understanding the regulatory to operational 
aspects help individuals understand the larger company goal. The handbook offers the 
opportunity to communicate with personnel beyond their current department that may 
resulting more efficient workflow management because the awareness of cross-functional 
impact is more likely to be acknowledged.  
For some, the need of a handbook would serve as a valuable onboarding tool if 
newer to the specific product or industry needs or may also provide as useful as a general 
reference tool. The author hopes that the results of this Biological Handbook serve as a 
useful resource to research administrators. The Handbook seeks to serve as an 
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This biological handbook is intended to serve as localized resource of 
fundamental information and regulations applicable to Product Regulatory Affairs (PRA), 
Genomics Division at the Company, specifically products manufactured and shipped 
from the Texas logistics center (TX-LC). The documentation provides an overview of 
product information and processes that comply with appropriate required quality 
management standards and regulations.  
The Company conducts business on a global level. The PRA division is aimed at 
aiding in the global market assessment by coordinating regulatory information that 
impact the Company. A basic workflow was developed to provide high-level overview of 
regulatory responsibility for the PRA team (Appendix I). 
The Genomics product portfolio of products manufactured and focuses in 
reagents, buffers, kits, accessories and their associated software.1 Due to the complexity 
and the objective of keeping this handbook as a basic reference guide, there may be 
regulatory elements not covered. Instead, references and key contact are offered as 
starting points for further review. Refer to Company standard operating procedures or 
work instruction for specific company processes. 
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Failure modes and effects analysis (FMEA) – Is a step-by-step approach for identifying 
all possible failures in a design, a manufacturing or assembly process, or a product or 
service.6  
Foreseeable Misuse - Unintended conduct that may result from readily predictable 
human behavior. Foreseeable misuse includes mistakes, lapses, slips or use of a product 
or system in a way not intended but which can result from readily predictable human 
behavior including well-meant optimization or readily available shortcuts.   
General Purpose Reagent (GPR) – “Chemical reagent that has general laboratory 
application, is used to collect, prepare, and examine specimens from the human body for 
diagnostic purposes, and is not labeled or otherwise intended for a specific diagnostic 
application (21CFR864.4010).” 7  
In vitro diagnostic medical device IVD – “A medical device intended by the 
manufacturer for the examination of specimens derived from the human body to provide 
information for diagnostic, monitoring or compatibility purposes.”8  
In vitro diagnostic products –  Defined as “chemical  reagents, instruments, and 
systems intended for use in the diagnosis of disease or other conditions, including a 
determination of the state of health, in order to cure, mitigate, treat, or prevent disease or 
its sequelae. Such products are intended for use in the collection, preparation, and 
examination of specimens taken from the human body (21CFR809).”9  
Indications for Use - The clinical conditions intended to be diagnosed or treated by the 
product.  
Intended Use – A key regulatory concept for all products. The intended use is 
demonstrated through labeling. The use for which a product, process or service is 
intended according to the specifications, instructions, and information provided by the 
manufacturer.10  
                                                          
6 "What Is FMEA? Failure Mode & Effects Analysis | ASQ,” Asq.Org, Last modified 2019, 
https://asq.org/quality-resources/fmea.   
7 “§ 864.4010 General Purpose Reagent,” Code of Federal Regulations, accessed August 1, 2019, 
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?FR=864.4010 
8 Kazunari Asanuma, Definition Of The Terms ‘Medical Device’ And ‘In Vitro Diagnostic (IVD) Medical 
Device’, ebook Global Harmonization Task Force, 2012, 
http://www.imdrf.org/docs/ghtf/final/sg1/technical-docs/ghtf-sg1-n071-2012-definition-of-terms-
120516.pdf.  
9 “§ 809 In Vitro Diagnostic Products for Human Use,” Code of Federal Regulations, accessed August 1, 
2019, https://www.law.cornell.edu/cfr/text/21/part-809 










Labeling – Refers to any “written, printed or graphic matter affixed to a medical device 
or any of its containers or wrappers, or accompanying a medical device, related to 
identification, technical description, and use of the medical device, but excluding 
shipping documents.11  
Manufacturer – Defined as “any person who designs, manufactures, fabricates, 
assembles, or processes a finished device. Manufacturer includes but is not limited to 
those who perform the functions of contract sterilization, installation, relabeling, 
remanufacturing, repacking, or specification development, and initial distributors of 
foreign entities performing these functions (CFR820.3).”12   
Manufacturing material – Defined as ”any material or substance used in or used to 
facilitate the manufacturing process, a concomitant constituent, or a byproduct 
constituent produced during the manufacturing process, which is present in or on the 
finished device as a residue or impurity not by design or intent of the manufacturer 
(21CFR820.3) .”13   
Medical Device – Defined by the WHO, “Any instrument, apparatus, implement, 
machine, appliance, implant, in vitro reagent or calibrator, software, material, or other 
similar or related article, intended by the manufacturer to be used, alone or in 
combination, for human beings for one or more of the specific purpose(s) of 
• diagnosis, prevention, monitoring, treatment or alleviation of disease, 
• diagnosis, monitoring, treatment, alleviation of or compensation for an injury, 
• investigation, replacement, modification, or support of the anatomy or of a 
physiological process, supporting or sustaining life, control of conception, 
disinfection of medical devices, 
• providing information for medical purposes by means of in vitro examination of 
specimens derived from the human body, and which does not achieve its primary 
intended action in or on the human body by pharmacological, immunological, or 
metabolic means, but which may be assisted in its function by such means, 
• aids for disabled/handicapped people, 
• devices for the treatment/diagnosis of diseases and injuries in animals, 
• accessories for medical devices, 
• disinfection substances, and,  
• devices incorporating animal and human tissues which can meet the requirements 
of the above definition but are subject to different controls.”14  
                                                          










Material Safety Data Sheet – Defined  by OSHA, “A Material Safety Data Sheet 
(MSDS) is a safety document required by the Occupational Safety and Health 
Administration (OSHA) that contains data about the physical properties of a particular 
hazardous substance.”15 
Original Equipment Manufacturer:  A company that uses product components from 
one or more other companies to build a product that it sells under its own company name 
and brand.  
Product Regulatory Affairs (PRA) – Company team that supports timely market access 
for products by requiring that products are compliant with appropriate regulations and 
meet customers’ stated expectations in terms of safety and environmental requirements. 
Product class – Defined as “those products intended for use for a particular 
determination or for a related group of determinations or products with common or 
related characteristics or those intended for common or related uses. A class may be 
further divided into subclasses when appropriate (21CFR809).”16 
Quality Management System (QMS) – the organizational structure, responsibilities, 
procedures, processes, and resources for implementing quality management 
(21CFR820.3).17  
Quality – The totality of features and characteristics that bear on the ability of a device to 
satisfy fitness-for-use, including safety and performance (21CFR820.3).18   
Reagents- A substance used to carry out a laboratory test. Reagents may be used in 
chemical reaction to detect, measure, or make other substances.19 
Risk - Combination of the probability of occurrence of harm and the severity of that 
harm. ISO14971 
Risk Assessment - The overall process comprising a risk analysis and a risk evaluation. 
ISO14971 
Risk Control - The process in which decisions are made and measures implemented by 
which risks are reduced to, or maintained within, specified levels. ISO14971 
                                                          
15 "OSHA MSDS Rules | MSDS Authoring Services Inc.,” MSDS Authoring, accessed 2 September 2019, 
https://msdsauthoring.com/msds-safety-data-sheet-chemicals-osha-msds-rules.  
16 “§ 809 In Vitro Diagnostic Products for Human Use,” Code of Federal Regulations, accessed August 1, 
2019, https://www.law.cornell.edu/cfr/text/21/part-809  
17 “§ 820.3 Quality System Regulation,” Code of Federal Regulations, accessed August 1, 2019, 
https://www.law.cornell.edu/cfr/text/21/part-820 
18 21CFR820.3 





Specification – Defined as “Any requirement with which a product, process, service, or 
other activity must conform (21CFR820.3).”20 
Substance – A substance refers to a “chemical and any associated compounds regardless 
of natural occurrence, any additives for preservation, but excluding any diluter that would 
change its composition (e.g. any constant chemical or pure substance that cannot be 
separated into different components).”21  
                                                          
20 21CFR820.3 
21 "Substances And Mixtures | Introduction To Chemistry,” Introduction To Chemistry, accessed 3 



















Category A – Infectious Substance: Any microorganism that has the ability to cause 
“permanent disability, life threatening or fatal disease in otherwise healthy humans or 
animals.”29 Infectious substances must be packed in accordance with IATA Dangerous 
Goods (DG) regulations. Refer to Section 3.2.3 for DG information. 
• UN Assignment(s): UN2814 & UN2900 
• Examples: Escherichia coli, verotoxigenic (cultures only), Ebola virus. Refer 
to IATA (3.6.2.2.2.1) for indicative examples 
Category B – Biological Substance: Other substances that contain infectious pathogens 
that does not meet the definition of Category A. 
• UN Assignment(s): UN3373 
• Examples: A blood sample containing Escherichia coli, instead of a culture 
3.1.2 Genetically Modified Organisms (GMO) or Genetically Modified Micro-
Organisms (GMMO)  
GMO/GMMOs are regulated similar to infectious disease categories but even 
though they do not meet the definition of an infectious disease. These modified 
organisms are still capable of altering its environment or animals.30 
• UN Assignment(s): UN3245 
                                                          
29 IATA,"Dangerous Goods Regulations. Classification of Infectious Substances," 3.6.2.2.2.1 § (2017). 
30 IATA, “Genetically Modified Micro-Organisms (GMMOs) or Genetically Modified Organisms (GMO),” 







All legal responsibility and compliance adherence are owned by our highly trained global 
trade team.  
3.2.1 Harmonized Tariff Schedule (HTS)32 
• A code required by importing authority to assess the duties and taxes on the 
products or items. 
• Used to determine trade compliance statistics 
3.2.2 Export Control Classification Number (ECCN) 
• Alphanumeric commodity code used to identify a product/items export licensing 
requirement. 
o All domestic companies are required to provide an ECCN to the US 
Government 
Please use the web-based interface trade automation tool to locate technical information 
about our products classification logic: A link will be provided for Company Use Only 
Corporate compliance policy: A link will be provided for Company Use Only 
3.2.3 Dangerous Goods 
Dangerous Goods (DG) are defined by IATA as “any solid, liquid, gas that may 
endanger a person or transport carrier during the shipment via air transport.”33 DG 
classification in conjunction with GHS is an integral component of the hazard 
                                                          
32 "A Harmonized System for Intended Use Codes,” Customsinfo.Com, accessed 1 October 2019, 
https://www.customsinfo.com/A-Harmonized-System-for-Intended-Use-Codes.  





substance/dangerous goods framework. Guided by GHS, DG classifications are managed 
and maintained by the Company’s logistics center. 
• DG via aircraft, refer to IATA- DG Global Reference Manual 
• DG via ground, refer to 49 CFR 171-180 – DOT Ground Transport 
DG Classification is required to ensure the following: 
• Safe Transport of hazardous materials per the trade requirements 
• Safety for all individuals involved in handling of the cargo 
• Ensure proper handling and packaging for loading/unloading of all goods 
3.2.4 Hazard Communication Standard (HCS) 
The identification of hazardous chemicals is crucial to workplace safety. Similar 
to GHS this accomplished through standardizing labeling, SDSs and training 
requirements as stated in 29CFR1910.1200.34 It is important to note that HSC has been 
aligned with GHS safety standards but inclusion of articles results in more hazard 
chemical classification that dangerous goods.  
3.2.5 Toxic Substance Control Act (TSCA) 
Under the management of the dangerous good program, the Company is 
responsible for the procurement of biological and chemical mixtures and substances 
information to provide to the US Environmental Protection Agency. Refer to 15 U.S.C. 
§§ 2601-2629 for detailed information about TSCA.  
In addition, 40 C.F.R. §§ 704.3 may provide definitions applicable to TSCA requirements.   
                                                          
34 "Hazard Communication | Occupational Safety and Health Administration,” Osha.Gov, accessed 25 






in the innovation of medications and foods for further public advancement.35 Biologic 
regulation, in addition to food, drug and medical devices are codified in 21 CFR by their 
associated functional areas. As a prominent regulatory agency responsible for such a 
wide range of consumer products, they are composed of various centers and 
organizations to take on the large scale of potential advancements. Refer to Appendix II 
for the current organizational structure of the FDA. 
Because of the diversity of biologics there are three centers that regulate 
biological products: (1) Center for Drug Evaluation and Research (CDER), (2) Center for 
Biologics Evaluation and Research (CBER), and (3) Center for Devices and Radiological 
Health (CDRH). 
This handbook outlines the three main centers and their responsibilities but the 
degree of applicable regulations for biological products will vary by individual classes 
and nature of products. Refer to Table 4.1 for centers responsible for biological products 

















                                                          





Table 4.1. FDA Centers with Biological Oversight 
 
4.1.1 Center for Drug Evaluation and Research 
The CDER regulates biological therapeutics and generic drugs that are distributed 
as over the counter and prescription drugs. This means all the biologically derived cells, 
molecules, tissues or other biologics listed in Chart 4.1 are intended to be used for the 
treatment, diagnosis, or prevention of diseases and are generally based by their 
therapeutic category.36 The CDER is concentrated in human safety, thus rely more on 
ICH guidelines. It should be noted that bio-therapeutics may be regulated under both 
CDER and CBER.  
The CBER regulates a large number of biological products intended for human 
use, this includes but is not limited to tissue-based products, blood products, vaccines, 
                                                          














structures. The organization identifies itself as independent, separating itself from 
government oversight to develop standards for international market needs.42 Refer to 
Chapter 9 for Company specific ISO certifications.  
                                                          




























effective in 2012, modification to the Hazard Communication Standards (HCS)49 was 
finalized to conform to GHS standards.  
Although GHS labeling is heavily concentrated on chemical information, it is still 
an important element of biological product considerations. Not only are biological 
components suspended in a chemical, but the biological risk should give proper warning 
by proper biosafety level identification.  
There are 6 main elements of UN GHS Labeling50:  
1. Signal Word - Indicates hazard level (Danger, Warning) 
2. GHS Symbols (Hazard Pictograms) – Identify chemical/physical, health or 
environment risks.  
• Refer to Appendix III for commonly used hazardous symbols. 
3. Manufacturer Information – Company name, address and telephone. 
4. Precautionary Statements/First Aid - Safety Data Sheet identified by P-Code 
5. Hazard Statements - Hazard and degree of hazards identified by H-Code 
6. Product Identifier: Manufacturer product number and name 
                                                          
49 Chapter 29, Parts 1910, 1915, and 1926,” Code of Federal Regulations, accessed October 27, 2019, 
https://www.osha.gov/laws-regs/federalregister/2012-03-26  






There are a large number of countries that have adopted the GHS process. Even 
so, many countries or their respective authorities have published their GHS guidelines 
due to their varying regulatory frameworks. Per GHS ver7 1.1.3.1.5, countries are to use 
a building block approach, allowing them to freely determine which elements of the GHS 
system they are willing to apply within their framework.  
Genomics specific product labeling requirements SOP: A link will be provided for 
Company Use Only 
8.3.2 Labeling in European Union    
 
Mandated by the European Parliament and the Council, GHS has slowly been 
implemented in the EU since the year 2004 by the European Chemical Agency (ECHA). 





(EC) No1272/2008: Regulation that refers to EU “classification, labeling and packaging 
of substances and mixtures” requirements into regulation.” 51  The regulation is 
commonly referred to as ‘CLP.’  
The bio-chemical composition is required for all final products. 
(EC) No 1272/2008: Click Here  
Annex VIII – The cataloguing of classifications of hazardous substances, per the 
EU, is published in Annex VIII. Recent guidance to help determine the criteria CLP sets 
forth for hazardous mixtures and its relationship identified hazardous materials in Annex 
VIII.52 
Guidance on Annex VIII to CLP (Version 22/07/2019): ECHA Documents   
8.3.3 Labeling in South Korea   
 
Chemical verification must be completed for all reagents or mixtures to verify 
status as regulated/unregulated substance. Chemical substances need to be registered for 
products accumulating to shipping more and 1 ton annually of chemical.  
Mandated by the National Institute for Environmental Research (NIER), the 
Republic of Korea has implemented some GHS requirements. Labeling products for 
South Korea exporting must include both the GHS labeling and the specific South Korea 
labeling. Relevant legislation regarding labeling and its resources have been provided for 
reference.  
                                                          
51 GHS Labeling Requirement, BRADY 













8.6.1 Declaration of Dangerous Goods 
Shipments that hold hazardous material must submit a DG declaration in addition 
to other appliable safety labeling. 
8.6.2 Animal Origin (AO) Declaration/Certificate  
Products that contain animal derived substances require a separate inspection 
process when entering customs. This is because the importation of biological products 
within contained sources of animal origin may add additional risks to the public. Special 
import conditions must be met during the transportation of products with AO, for 
example, splitting the delivery and separating the non-animal origin products may reduce 
the risks of contamination. Refer to our Company’s EHS database for specific 
information regarding the biological compositions of production.  
AO Declaration elements:  
• Product name: Trading name of product(s) that appear on packaging must match; 
• Description: All imported products must list any raw material sourced with 
animal origin, species and concentration; 
• Biological information: biological composition (w/v%), exact weight and CAS 
number if applicable; 
• End Use:  Statement for end use that must match their US FDA export certificate 
and, 




8.6.2.1 Germany: EU Veterinary Regulations 
Shipment requires supporting documentation for products that contain animal 
origin. Enforced by customs Veterinary authorities, AO products may only enter with the 
require AO documentation.  Declarations are generated during the transfer order created 
by our logistics team.  
Animal origin documentation may include: 
• AO Declaration 
• Certificate of Analysis 
• Process Statement 
• Product Specification Sheet 
8.6.2.2 South Korea: AO Declaration per shipment 
Biological products are subject to customs quarantine process enforced by the 
Animal and Plant Quarantine Agency (APQA).  
The manufacturer (Company) must provide an export certificate and be endorsed prior to 
shipping products that contain animal derived materials or are classified as blood 
products. The US Department of Agriculture (USDA) provides guidance on the 






Per the USDA54 basic information required on all export certificates include: 
• Product name and any species of origin 
• Number of packages- packages are considered by the sellable part-number 
• Total weight 
• Shipping container number and seal 
• Date of shipment 
• Name of the vessel or aircraft used for transportation 
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List of Abbreviations 
 
BOM Bill-Of-Material 
CAPA A Corrective and Preventative Action  
CLP Classification, Labeling and Packaging 
DGG Diagnostic and Genomics Group 
Early Access / EA Early customer access  
FDA United States Food and Drug Administration 
GDP Good Documentation Practices 
GMP Good Manufacturing Practices                                  
GSD Genomics Solutions Division  
IDE Investigational Device Exemption                       
ISO  International Organization for Standardization                 
LC Logistics Center 
MSDS/SDS (Material) Safety Data Sheets 
NGS Next generation Sequencing  
NIH National Institutes of Health                                                 
QA Quality Assurance 
R&D Research and Development  
RA Regulatory Affairs 
RAMM Risk Analysis and Mitigation Matrix.  
RUO Research Use Only  
SAP Systems, Applications and Products 
SCM Supply Chain Management 
SNP Single Nucleotide Polymorphism  
SOP Standard Operating Procedure 
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